

OVERVIEW

Heart failure is one of the most challenging health problems worldwide, with increased life expectancy and better treatments for cardiovascular diseases leading to an increase in occurrence. Many drugs are available to improve the prognosis of these patients, including new compounds recently demonstrated to reduce mortality. However, despite the range of therapeutic interventions available to treat this disease, its management remains a big challenge for the healthcare community, especially when care aims to combine standard therapeutic strategy with novel findings from the most recent clinical trials.

LEARNING OBJECTIVES

By participating in this online interactive activity, learners will be able to:

1. Confidently assess the clinical condition of the patient in order to choose the most appropriate treatment for them, thus providing optimal prognosis and outcome
2. Understand how to combine established treatments with newly available drugs, utilizing the evidence of recent controlled clinical trials
3. Identify how treatment may be improved and what is the best strategy to manage patient follow-up

TARGET AUDIENCE

This activity is designed for Cardiologists, General Practitioners, Internists and specialists involved in the diagnosis and management of patients with cardiovascular disease and hypertension.



FACULTY

Stefano Taddei

Director of the Hypertension Unit
Department of Clinical and Experimental Medicine
University of Pisa, Italy

For information about the program, please contact:

Scientific Seminars International Foundation

T +39 380 1504116 - F +39 06 4827169

info@scientificseminars.com

To access the resource online, click here and login:

<https://www.elearning.scientificseminars.com/the-2020-blended-learning-journey-on-cardiovascular-risks-for-emea/interactive-clinical-case/>

This independent educational program is made possible thanks to an educational grant received from Merck KGaA, Darmstadt, Germany.